小儿咳喘灵颗粒辅助治疗小儿支气管肺炎风寒袭肺证45例临床观察

Clinical efficacy of Xiao'erKechuanlingKeli(小儿咳喘灵颗粒)inthe adjuvant treatment of pediatric bronchopneumonia with wind-cold attacking lung syndrome

目的 观察小儿咳喘灵颗粒辅助治疗小儿支气管肺炎风寒袭肺证的临床疗效。方法 选取2019年1月至2021年1月温州医科大学附属新昌医院新生儿科收治的支气管肺炎风寒袭肺证患儿90例,采用随机数字表法分为治疗组和对照组,各45例。对照组给予布地奈德、异丙托溴铵、阿莫西林克拉维酸钾治疗,治疗组在对照组治疗方法的基础上联合小儿咳喘灵颗粒治疗,2组均治疗7 d后统计临床疗效。结果 治疗组总有效率为95.56%(43/45),显著高于对照组的82.22%(37/45),2组比较,差异有统计学意义(P<0.05)。治疗前,2组咳嗽、气促、咳痰、发热积分和血清淀粉样蛋白(SAA)、降钙素原(PCT)水平比较,差异均无统计学意义(P>0.05),具有可比性;治疗后,2组的上述中医证候积分和血清炎症因子SAA、PCT水平与同组治疗前比较,均显著降低(P<0.05),且治疗组降低更显著,差异有统计学意义(P<0.05)。治疗组总不良反应率为6.67%(3/45),对照组为11.11%(5/45),2组比较,差异无统计学意义(P>0.05)。结论 小儿咳喘灵颗粒辅助治疗小儿支气管肺炎风寒袭肺证疗效满意,不仅可有效抑制局部炎症反应,降低中医证候积分,而且无明显不良反应,值得临床推广应用。

Objective To observe the clinical efficacy of Xiao'er Kechuanling Keli(小儿咳喘灵颗粒)in the adjuvant treatment of infantile bronchopneumonia with wind-cold attacking lung syndrome.Methods Ninety cases of bronchopneumonia with wind-cold attacking lung syndrome admitted to the department of neonatology,Xinchang People's Hospital Affiliated to Wenzhou Medical University from January 2019 to January 2021 were selected and divided into a treatment group and a control group in a random number table,with 45 cases each.The control group was given budesonide,ipratropium bromide and amoxicillin clavulanate potassium,while the treatment group was combined with Xiao'er Kechuanling Keli(小儿咳喘灵颗粒)on the basis of the treatment of the control group.The clinical efficacy of both groups was counted after 7 days of treatment.Results The total effective rate of the treatment group was 95.56%(43/45),which was significantly higher than that of the control group,which was 82.22%(37/45),and the difference between the two groups was statistically significant(P<0.05).Before treatment,there was no statistically significant difference between the two groups in cough,shortness of breath,coughing sputum,fever score and serum inflammatory factors amyloid A(SAA)and procalcitonin(PCT)levels(P>0.05),which were comparable.Compared with those before treatment in the same group,after treatment,the above-mentioned TCM symptoms score and serum inflammatory factors serum SAA and PCT levels in the two groups were significantly reduced(P<0.05),and the reduction was more significant in the treatment group,meanwhile,the difference was statistically significant(P<0.05).The overall adverse reaction rate was 6.67%(3/45)in the treatment group and 11.11%(5/45)in the control group,and the difference between the two groups was not statistically significant(P>0.05).Conclusion The adjuvant treatment of infantile bronchopneumonia with wind-cold attacking the lung syndrome with Xiao'erKechuanling Keli(小儿咳喘灵颗粒)has satisfactory efficacy,which not only can effectively inhibit the local inflammatory reaction and reduce the TCM syndrome score,but also has no obvious adverse effects,and is worthy of clinical promotion and application.